Published in Cancer Weekly, August 9th, 2005
The new indication - Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer - will mean that more postmenopausal women whose breast cancer is fueled by the hormone, oestrogen - about 75% of all postmenopausal cases - are now eligible to receive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.